Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD

Blood (2019) 134 (Supplement_1): 2929.

https://doi.org/10.1182/blood-2019-127959

Published: 2019

Journal Articles

Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice

Michael J. Mauro, MD, Clara Chen, PhD BS, MS, Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2018-99-115903

Published: 2018

Journal Articles

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Michael J. Mauro, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, PharmD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2018-99-118119

Published: 2018

Journal Articles

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Ravi Vij, MBBS, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Catherine Davis, PharmD, David J. Kuter, MD

Blood (2018) 132 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2018-99-112074

Published: 2018

Journal Articles

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Gordon Cook, David Cella, PhD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Brian GM Durie, MD, Hartmut Goldschmidt, MD, David J. Kuter, MD, Philippe Moreau, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2018-99-112081

Published: 2018

Journal Articles

Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble

David J Kuter, MD DPhil, Clara Chen, PhD BS, MS, Sergey Popov, Catherine Davis, Ravi Vij, MD MBBS

Blood (2017) 130 (Supplement 1): 3157.

https://doi.org/10.1182/blood.V130.Suppl_1.3157.3157

Published: 2017

Journal Articles

Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble

Ravi Vij, MD MBBS, Clara Chen, PhD BS, MS, Sergey Popov, Brian Durie, Gordon Cook, MD PhD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Catherine Davis, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3123.

https://doi.org/10.1182/blood.V130.Suppl_1.3123.3123

Published: 2017

Journal Articles

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Clara Chen, PhD BS, MS, Ravi Potluri, Hemanth Kanakamedala, Eros Papademetriou, Christopher A. Yasenchak, MD, Sandip Ranjan, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 3127.

https://doi.org/10.1182/blood.V130.Suppl_1.3127.3127

Published: 2017

Journal Articles

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Ravi Potluri, Hemanth Kanakamedala, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Sandip Ranjan, Eros Papademetriou, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 1844.

https://doi.org/10.1182/blood.V130.Suppl_1.1844.1844

Published: 2017

Journal Articles

An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy

Brian Durie, MD, David J Kuter, MD DPhil, Catherine Davis, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Hartmut Goldschmidt, Ravi Vij, Sergey Popov, David Cella, PhD, Gordon Cook, MD PhD

Blood (2016) 128 (22): 2403.

https://doi.org/10.1182/blood.V128.22.2403.2403

Published: 2016

Journal Articles

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

Gordon Cook, MD PhD, David Cella, PhD, Brian Durie, MD, Hartmut Goldschmidt, MD, David Kuter, MD DPhil, Philippe Moreau, Ravi Vij, MD MBBS, Catherine Davis, Abderrahim Oukessou, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Sergey Popov, Antonio Palumbo, MD

Blood (2015) 126 (23): 2093.

https://doi.org/10.1182/blood.V126.23.2093.2093

Published: 2015

Journal Articles

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Initial Assessment of Treatment Patterns in Patients with ≥6 Months Follow-up

Ravi Vij, MD, Lieven Annemans, PhD, Catherine Davis, Pharm.D., Trong K. Le, MPH, MS, Blake Bartlett, PhD, Philippe Moreau, MD

Blood (2014) 124 (21): 1297.

https://doi.org/10.1182/blood.V124.21.1297.1297

Published: 2014

Journal Articles

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, MD, Rüdiger Hehlmann, MD, Carlo Gambacorti-Passerini, MD, Stuart Goldberg, MD, H. Jean Khoury, MD, Michael Mauro, MD, Mauricette Michallet, MD, PhD, Ron Paquette, MD, PhD, Bengt Simonsson, MD, PhD, Aimee Foreman, PhD, Hesham Mohamed, MD, Teresa Zyczynski, Pharm.D., MPH, Ishan Hirji, MPH, Catherine Davis, Pharm.D.

Blood (2013) 122 (21): 4026.

https://doi.org/10.1182/blood.V122.21.4026.4026

Published: 2013

Journal Articles

Associations Between Treatment Restrictions, Patient-Reported Treatment Burden and Adherence to Tyrosine-Kinase Inhibitor Therapy Among Chronic Myeloid Leukemia Patients in the United States and Europe

Shaloo Gupta, M.S., Amir Goren, Ph.D., Timothy W Victor, Ph.D., Jonathan Chapnick, Stephanie Hawthorne, PhD, Ishan Hirji, MPH, Eduardo Olavarría, MD, Alyson B Moadel, Ph.D., Colleen Lemoine, APRN, MN, AOCN, RN-BC, Catherine Davis, Pharm.D.

Blood (2011) 118 (21): 2077.

https://doi.org/10.1182/blood.V118.21.2077.2077

Published: 2011

Journal Articles

Treatment Adherence in Patients with Chronic Myeloid Leukemia in a Real World Setting

Susan A Oliveria, ScD, MPH, FISPE, Marianne Ulcickas Yood, DSc, MPH, FISPE, Ishan Hirji, MPH, Syd Phillips, MPH, Mark Cziraky, PharmD, FAHA, CLS, Catherine Davis, Pharm.D.

Blood (2011) 118 (21): 4424.

https://doi.org/10.1182/blood.V118.21.4424.4424

Published: 2011

Journal Articles

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, Michael J. Mauro, MD, Stuart L. Goldberg, MD, Ron Paquette, MD, PhD, H. Jean Khoury, MD, FACP, Ishan Hirji, MPH, Samuel Wagner, PhD, RPh, Sam Joo, PhD, Catherine Davis, PharmD

Blood (2011) 118 (21): 4435.

https://doi.org/10.1182/blood.V118.21.4435.4435

Published: 2011

Journal Articles

Adherence to Treatment In Patients with Chronic Myelogenous Leukemia During a 10-Year Time Period: A Medical Record Review.

Marianne Ulcickas Yood, DSc, MPH, Susan A Oliveria, ScD, MPH, Ishan Hirji, MPH, Mark Cziraky, PharmD, FAHA, CLS, Catherine Davis

Blood (2010) 116 (21): 1235.

https://doi.org/10.1182/blood.V116.21.1235.1235

Published: 2010

Journal Articles

Comorbidities and Conmedication Use In Patients with Chronic Myelogenous Leukemia.

Susan A Oliveria, ScD, MPH, Marianne Ulcickas Yood, DSc, MPH, Ishan Hirji, MPH, Mark Cziraky, PharmD, FAHA, CLS, Catherine Davis

Blood (2010) 116 (21): 4492.

https://doi.org/10.1182/blood.V116.21.4492.4492

Published: 2010

Journal Articles

Assessing the Experience of Living with Chronic Myeloid Leukemia (CML) From the Patient's Perspective: Results of a Patient Survey

Timothy W Victor, Ph.D., Ishan Hirji, Ian Hicks, Jonathan Chapnick, Catherine Davis, PharmD, Erkut Bahceci, MD

Blood (2010) 116 (21): 4755.

https://doi.org/10.1182/blood.V116.21.4755.4755

Published: 2010

Journal Articles

Comparative Efficacy of First Line Treatment of Chronic Myeloid Leukaemia (CML): A Systematic Review and Meta-Analysis.

Stuart Mealing, MSc, Leticia Barcena, Ldo.Vet, Neil Hawkins, PhD, James Clark, MBiochem, Catherine Davis, PharmD

Blood (2010) 116 (21): 3436.

https://doi.org/10.1182/blood.V116.21.3436.3436

Published: 2010

NARROW

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble

Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Initial Assessment of Treatment Patterns in Patients with ≥6 Months Follow-up

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Associations Between Treatment Restrictions, Patient-Reported Treatment Burden and Adherence to Tyrosine-Kinase Inhibitor Therapy Among Chronic Myeloid Leukemia Patients in the United States and Europe

Treatment Adherence in Patients with Chronic Myeloid Leukemia in a Real World Setting

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Adherence to Treatment In Patients with Chronic Myelogenous Leukemia During a 10-Year Time Period: A Medical Record Review.

Comorbidities and Conmedication Use In Patients with Chronic Myelogenous Leukemia.

Assessing the Experience of Living with Chronic Myeloid Leukemia (CML) From the Patient's Perspective: Results of a Patient Survey

Comparative Efficacy of First Line Treatment of Chronic Myeloid Leukaemia (CML): A Systematic Review and Meta-Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only